Abstract
Background Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) plasma viremia has been associated with severe disease and death in coronavirus disease 2019 (COVID-19) in small-scale cohort studies. The mechanisms behind this association remain elusive.
Methods We evaluated the relationship between SARS-CoV-2 viremia, disease outcome, inflammatory and proteomic profiles in a cohort of COVID-19 emergency department participants. SARS-CoV-2 viral load was measured using qRT-PCR based platform. Proteomic data were generated with Proximity Extension Assay (PEA) using the Olink platform.
Results Three hundred participants with nucleic acid test-confirmed COVID-19 were included in this study. Levels of plasma SARS-CoV-2 viremia at the time of presentation predicted adverse disease outcomes, with an adjusted odds ratio (aOR) of 10.6 (95% confidence interval [CI] 4.4, 25.5, P<0.001) for severe disease (mechanical ventilation and/or 28-day mortality) and aOR of 3.9 (95%CI 1.5, 10.1, P=0.006) for 28-day mortality. Proteomic analyses revealed prominent proteomic pathways associated with SARS-CoV-2 viremia, including upregulation of SARS-CoV-2 entry factors (ACE2, CTSL, FURIN), heightened markers of tissue damage to the lungs, gastrointestinal tract, endothelium/vasculature and alterations in coagulation pathways.
Conclusions These results highlight the cascade of vascular and tissue damage associated with SARS-CoV-2 plasma viremia that underlies its ability to predict COVID-19 disease outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Direct funding for this project was provided in part by a grant from Mark, Lisa and Enid Schwartz (to J.Z.L.), the National Institute of Health (N.H., U19AI082630), an American Lung Association COVID-19 Action Initiative grant (M.B.G.), and grants from the Executive Committee on Research at MGH (M.B.G. and M.R.F.), the Chan-Zuckerberg Initiative (A-C.V.). N.H. was also funded by a gift from Arthur, Sandra and Sarah Irving for the David P. Ryan, MD Endowed Chair in Cancer Research. M.G. is the recipient of an EMBO Long-Term Fellowship (ALTF 486-2018) and a Cancer Research Institute/Bristol-Myers Squibb Fellow (CRI2993). This work was also supported by the Harvard Catalyst / Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Awards UL1 TR 001102 and UL1 TR 002541-01) and by the Harvard University Center for AIDS Research (NIAID 5P30AI060354). We are also very grateful for the generous contributions of Olink Proteomics Inc. and Novartis (in collaboration with SomaLogic,Inc.) for providing in-kind all proteomics assays presented in this work, without which our findings would not have been possible.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approved by Mass General Brigham IRB Protocol #: 2017P001681
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest The authors have declared that no conflict of interest exists.
Data Availability
Data will be available once the manuscript is formally accepted after peer-review.
